UBS Adjusts ALI HEALTH Target Price to HK$3.6, Citing Diminished Profit Visibility from Increased Investments

Stock News15:48

UBS has released a research report indicating that ALI HEALTH (00241) fell short of revenue expectations for the 2026 fiscal year. Furthermore, due to increased investments in artificial intelligence and supply chain, its adjusted net profit guidance for the 2027 fiscal year is below market expectations. The bank believes the company's profit visibility has declined, maintaining a "Sell" rating. In response to slowing revenue growth and margin pressure, UBS has lowered its profit forecasts for the group for the 2027 to 2029 fiscal years by 12% to 14%, and reduced the target price from HK$4.1 to HK$3.6. The report notes that ALI HEALTH's management has upgraded its business strategy, focusing on innovative drugs by integrating B2C and O2O operations and developing medical AI. UBS believes that while a drug-focused strategy may provide a downside cushion for revenue growth, the increasing proportion of revenue from first-party products and first-party drug sales, coupled with ongoing investments, will suppress profit margins. Additionally, heightened investments and competition from key rival JD Health (06618) may further increase profit uncertainty.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195588876?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195588876","market":"us","top_or_hot":-1,"title":"UBS Adjusts ALI HEALTH Target Price to HK$3.6, Citing Diminished Profit Visibility from Increased Investments","media":"Stock News","content":"<p>UBS has released a research report indicating that ALI HEALTH (00241) fell short of revenue expectations for the 2026 fiscal year. Furthermore, due to increased investments in artificial intelligence and supply chain, its adjusted net profit guidance for the 2027 fiscal year is below market expectations. The bank believes the company's profit visibility has declined, maintaining a \"Sell\" rating. In response to slowing revenue growth and margin pressure, UBS has lowered its profit forecasts for the group for the 2027 to 2029 fiscal years by 12% to 14%, and reduced the target price from HK$4.1 to HK$3.6. The report notes that ALI HEALTH's management has upgraded its business strategy, focusing on innovative drugs by integrating B2C and O2O operations and developing medical AI. UBS believes that while a drug-focused strategy may provide a downside cushion for revenue growth, the increasing proportion of revenue from first-party products and first-party drug sales, coupled with ongoing investments, will suppress profit margins. Additionally, heightened investments and competition from key rival JD Health (06618) may further increase profit uncertainty.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Adjusts ALI HEALTH Target Price to HK$3.6, Citing Diminished Profit Visibility from Increased Investments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Adjusts ALI HEALTH Target Price to HK$3.6, Citing Diminished Profit Visibility from Increased Investments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-18 15:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS has released a research report indicating that ALI HEALTH (00241) fell short of revenue expectations for the 2026 fiscal year. Furthermore, due to increased investments in artificial intelligence and supply chain, its adjusted net profit guidance for the 2027 fiscal year is below market expectations. The bank believes the company's profit visibility has declined, maintaining a \"Sell\" rating. In response to slowing revenue growth and margin pressure, UBS has lowered its profit forecasts for the group for the 2027 to 2029 fiscal years by 12% to 14%, and reduced the target price from HK$4.1 to HK$3.6. The report notes that ALI HEALTH's management has upgraded its business strategy, focusing on innovative drugs by integrating B2C and O2O operations and developing medical AI. UBS believes that while a drug-focused strategy may provide a downside cushion for revenue growth, the increasing proportion of revenue from first-party products and first-party drug sales, coupled with ongoing investments, will suppress profit margins. Additionally, heightened investments and competition from key rival JD Health (06618) may further increase profit uncertainty.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1501","symbol_name":"阿里概念股","start_time":0,"source_url":"","article_id":"1195588876","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195588876","pubTimestamp":1779090504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UBS has released a research report indicating that ALI HEALTH (00241) fell short of revenue expectations for the 2026 fiscal year. Furthermore, due to increased investments in artificial intelligence...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1501":"阿里概念股","BK1571":"互联网医疗","BK1617":"AI医疗","00241":"阿里健康","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1610":"ETF&股票定投概念","BK1189":"医疗保健技术","BK1247":"药品零售","BK1142":"互联网与直销零售","BK1502":"双十一","BK1591":"就地过年概念","EWH":"香港ETF-iShares MSCI","BK1615":"港股-互联网","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1584":"蚂蚁金服概念"},"translate_title":"瑞银将阿里健康目标价调整至3.6港元，理由是投资增加导致盈利能见度下降","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWH":1,"00241":1},"content_text":"UBS has released a research report indicating that ALI HEALTH (00241) fell short of revenue expectations for the 2026 fiscal year. Furthermore, due to increased investments in artificial intelligence and supply chain, its adjusted net profit guidance for the 2027 fiscal year is below market expectations. The bank believes the company's profit visibility has declined, maintaining a \"Sell\" rating. In response to slowing revenue growth and margin pressure, UBS has lowered its profit forecasts for the group for the 2027 to 2029 fiscal years by 12% to 14%, and reduced the target price from HK$4.1 to HK$3.6. The report notes that ALI HEALTH's management has upgraded its business strategy, focusing on innovative drugs by integrating B2C and O2O operations and developing medical AI. UBS believes that while a drug-focused strategy may provide a downside cushion for revenue growth, the increasing proportion of revenue from first-party products and first-party drug sales, coupled with ongoing investments, will suppress profit margins. Additionally, heightened investments and competition from key rival JD Health (06618) may further increase profit uncertainty.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195588876","isCrawlerRequest":true}